摘要
目的探讨培美曲塞联合顺铂化疗对晚期非小细胞肺癌患者细胞免疫功能的影响及其临床意义。方法对经细胞或组织病理学确诊的40例晚期非小细胞肺癌(腺癌)患者给予培美曲塞500mg/m^2,dl静脉滴注,顺铂25mg/m^2,d1～d3静脉滴注,21d为1周期,共治疗2个周期。采集正常健康者与患者治疗前后外周血标本,应用流式细胞仪检测CD^(3+)、CD^(4+)、CD^(8+)T细胞和NK细胞的表达水平。结果与正常健康者相比,晚期非小细胞肺癌(腺癌)患者化疗前后CD^(3+)、CD^(4+)T细胞、CD^(4+)/CD^(8+)比值和NK细胞水平下降,CD^(8+)T细胞水平升高,差异有统计学意义(P<0.05);与化疗前相比,化疗后CD^(3+)、CD^(4+)T细胞、CD^(4+)/CD^(8+)比值和NK细胞水平升高,CD^(8+)T细胞水平下降,差异有统计学意义(P<0.05)。结论培美曲塞联合顺铂化疗能增强晚期非小细胞肺癌(腺癌)患者的细胞免疫功能,可以将细胞免疫功能作为一项判断患者预后的指标。
Objective To explore the effect of combined chemotherapy with pemetrexed and cisplatin on immunity of patients with Advanced non - small - cell lung cancer（NSCLC）. Methods 40 patients with advanced gland -type NSCLC confirmed by the cellular or tissue pathologies received combined use of pemetrexed of 500mg/m2 on 1st day and eisplatin, and cisplatin of 75mg/m2 on 1st to d 3rd days for 21 days as a course. Before and after the consecutive therapy course, peripherial blood was collected from normal persons and patients. Flow eytometry was employed to detect the expression levels of CD3＋ , CD4＋ , CD8＋ T lymphocytes and NK cells. Results Compared with the control group, the treatment group got decreased expression levels of CD3＋, CD4＋ T lymphocytes, CD4＋/CD8＋ ratio and NK cells but increased level of CD8＋ T lymphocyte was observed in advanced gland -type NSCLC patients before and after treatment（ P 0.05）. While after being treated with this chemotherapy regimen, increased levels of CD3＋ , CD4＋ T lyrnphocytes, CD4＋/CD9＋ ratio and NK cells but decreased level of CD8＋ T lyrnphocyte were observed in the patients（ P 〈0.05）. Conclusion Combined Chemotherapy with pemetrexed and eisplatin can enhance the cellular immune function of advanced gland -type NSCLC patients. The cellular immune function can be used as a prognostic indicator of the patients.
出处
《山东医学高等专科学校学报》
2012年第6期407-410,共4页
Journal of Shandong Medical College
关键词
非小细胞肺癌
T细胞亚群
细胞免疫
培美曲塞
顺铂
Non-small cell lung cancer
T lymphocyte subsets
Cellular immunity
Pemetrexed
Cisplatin
